<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278391</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1421101</org_study_id>
    <nct_id>NCT04278391</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Between &quot;DWJ1421&quot; and &quot;DWC201903&quot; in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Single Dose, Crossover Study to Compare the Pharmacokinetics and Safety Between &quot;DWJ1421&quot; and &quot;DWC201903&quot; in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, single dose, crossover study to compare the
      pharmacokinetics and safety between &quot;DWJ1421&quot; and &quot;DWC201903&quot; in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">August 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14h</time_frame>
    <description>Maximum concentration of DWJ1421</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>0, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14h</time_frame>
    <description>Area under the drug concentration-time curve</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A (RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (TR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1421</intervention_name>
    <description>1 tablet administered in fasting condition</description>
    <arm_group_label>B (TR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWC201903</intervention_name>
    <description>1 tablet administered in fasting condition</description>
    <arm_group_label>A (RT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 19 aged and 45 aged in healthy male adult

          -  Body weight more than 50kg

          -  Body Mass Index more than 18.0 and under 27.0

        Exclusion Criteria:

          -  Those who have clinical significant liver, kidney, digestive system, respiratory,
             endocrine, nervous system, hematology and oncology, cardiovascular, urinary diseae or
             past history

          -  Those who have a gastrointestinal disease history that can effect drug absorption or
             surgery

          -  Those who have hypersensitivity reaction or clinically significant hypersensitivity
             reaction in the history of Investigational product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bundang CHA Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

